Analysts Offer Predictions for Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Kura Oncology in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will earn ($2.94) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

A number of other research analysts also recently commented on the stock. Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. HC Wainwright lifted their price target on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, November 21st. Bank of America cut their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, November 22nd. UBS Group assumed coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. Finally, JMP Securities reissued a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Stock Performance

Kura Oncology stock opened at $7.39 on Wednesday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $10.08 and a 200-day moving average of $16.15. The stock has a market cap of $574.68 million, a P/E ratio of -3.13 and a beta of 0.81. Kura Oncology has a 52 week low of $6.98 and a 52 week high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same period in the previous year, the company posted ($0.50) earnings per share.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently modified their holdings of the company. Harbor Capital Advisors Inc. lifted its position in Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after buying an additional 3,092 shares during the last quarter. Armistice Capital LLC boosted its position in shares of Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after buying an additional 302,000 shares during the period. Alethea Capital Management LLC grew its holdings in Kura Oncology by 2.4% in the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock worth $5,475,000 after buying an additional 6,300 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after acquiring an additional 58,422 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.